Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Metastatic Carcinoma in the Liver: early-phase trial registry

1 of 3 indexed Metastatic Carcinoma in the Liver trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count

Metastatic Carcinoma in the Liver: 3 US clinical trials tracked, 1 recruiting.

Metastatic Carcinoma in the Liver is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Roswell Park Cancer Institute, running 1 of these trials.

Enrollment posture brief

Registry condition metastatic-carcinoma-in-the-liver

OPEN 1 | RECR 33% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Metastatic Carcinoma in (th…33%
Open-enrollment share among volume-matched conditions near Metastatic Carcinoma in the Liver

Metastatic Carcinoma in the Liver lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Metastatic Carcinoma in the Liver on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Metastatic Carcinoma in the Liver is recruiting below its size-band peers.

    1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 22

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2

Named interventions

Most-linked intervention names on Metastatic Carcinoma in the Liver records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Anti-GITR Agonistic Monoclonal Antibody BMS-986156 Drug
1 trials
Rintatolimod Drug
1 trials
Recombinant Interferon Alfa-2b Biological
1 trials
Ipilimumab Biological
1 trials
Nivolumab Biological
1 trials
Celecoxib Drug
1 trials
Cemiplimab Biological
1 trials
Laboratory Biomarker Analysis Other
1 trials

US sites by state

Facility locations filed on Metastatic Carcinoma in the Liver trials. A trial with sites in several states counts in each.

Texas 1 trials
New York 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Metastatic Carcinoma in the Liver page

3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Carcinoma in the Liver condition card totals 3 registered trials; most-linked intervention Anti-GITR Agonistic Monoclonal Antibody BMS-986156; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.